Information Provided By:
Fly News Breaks for December 16, 2015
ARRY
Dec 16, 2015 | 09:50 EDT
Piper Jaffray analyst Edward Tenthoff says binimetinib meeting the primary endpoint today in a Phase III trial paves the way for Array BioPharma's first approval in 2016. Binimetinib would be the first targeted therapy for NRAS mutant melanoma patients with projected U.S. sales of $166M in 2020, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Array with a $14 price target.